Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice little dip to add shares on...then break $2.
$COEP
That’s when all the Billionaires wake up….
I've noticed that we like to run in the afternoon let's see!!!
$COEP $1.78 Up +9.20% Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling; Coeptis strengthens measures to protect shareholder interests through ShareIntel's investigation and due diligence services https://finance.yahoo.com/news/coeptis-therapeutics-shareintel-enter-shareholder-130000396.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
Looking forward to further updates from the company!
$COEP
Awesome day up yet another 12%
$$$$$$
It's probably not much of a secret anymore with this little run.
$COEP
This is a very good hidden secret..lol
Was $1.40 a few days ago..
$1.78 is the BID now...and $1.80 hit as we come up on Power Hour. It's trading 2.1x its 10-day average volume... UP almost 8%.
$COEP
Nobody's even paying attention..
Lol
Get through $1.78 and it thins out considerably...
$COEP
It's trading 30% over its 10-day average volume lunchtime...UP almost 5%, some really good volume and price action lately.
$COEP
Could still close at the high of the day!
$COEP
$COEP Power Hour is definitely providing some Power...
Sweet... Looking forward to seeing further updates from the company!
$COEP
I'm hearing good things coming...
It's trading 60% over its 10-day average volume as we head into Power Hour...UP almost 4%, a nice continuation from yesterday.
$COEP
$COEP nice buys going, green heading into power hour!
Nice day from $1.40
It's trading nearly 80% over its 10-day average volume as we head into the close...UP almost 14%. Nice jump in volume and price from the past 2 weeks.
$COEP
$COEP +14.23% closing strong!
$1.39 on the ASK now as Power Hour saw some increased buying...
$COEP
Get through $1.40 and it could move quickly with volume.
Like $COEP Coeptis Therapeutics Inc (COEP) Companies Fight Back Against Market Manipulation and Illegal Short Selling; Here are Four other Stocks in the News $GNS $HLBZ $CPMD $VERB
https://quantisnow.com/insight/4020952
Agree, 1.5+ looks thin here
$COEP
Great opportunity to add shares at these levels while it's quiet.
$COEP
Loading zone under $2 here!
$COEP
Yeah, I was looking at the chart and events... I had something similar happen on another OTC to NASDAQ stock.
Lots of potential here and access to a larger group of investors. It'll take some time.
$COEP
Looking forward to it. We are at around .43 presplit. Many of us bought $3 presplit…. COEP was better off as an OTC play…
LoL, that would require more volume. Last week we averaged a little less than 100k and today we're at 36k. BID moving lower on small volume hits.
$COEP Big things ahead for this NASDAQ:
Would be interesting if price would go back up…..
$COEP 1.45 thin on the ask now!
Very interesting information... $COEP
THE IMPORTANCE OF CAR T CELL THERAPY
Chimeric antigen receptor (CAR) therapy is a new treatment for cancer in which a patient's T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Cells are extracted from the patient and then genetically engineered to make the CAR and are re-introduced back into the patient. Currently approved CAR T therapies are revolutionizing the treatment of many blood cancers including B cell leukemias and lymphomas by targeting specific proteins found on these cancers, and there is hope in treating additional cancers including solid tumors by having them recognize new targets.
$COEP Coeptis has licensed a CAR T cell therapy platform called "SNAP-CAR" to be a universal therapeutic
https://coeptistx.com/our-science/snap-car-t
Nope…. Still institutional investors from BHSE selling off…
We could see $COEP News on trials for other cancers...
All this paid SM promotion and chatter and it still goes nowhere
$COEP and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling https://finance.yahoo.com/news/coeptis-therapeutics-shareintel-enter-shareholder-130000396.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$COEP Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling
https://www.prnewswire.com/news-releases/coeptis-therapeutics-and-shareintel-enter-shareholder-service-agreement-targeting-illegal-short-selling-301740015.html
$COEP Coeptis Therapeutics CEO David Mehalick telling Proactive SNAP-CAR, which Coeptis licensed from the University of Pittsburgh, is being researched with tech that can be adapted to different cancer indications #nasdaq #coep #cancer #stock
$COEP - About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.
$COEP - Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers
$COEP trading just under 30% of its 10-day average volume as Power Hour approaches...but UP almost 7% and at the high of the day.
$COEP 1.69 up, green heading into power hour!
Thank you for sharing that link to the $COEP video.
Followers
|
109
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
11906
|
Created
|
03/04/10
|
Type
|
Free
|
Moderators |
"Coeptis Therapeutics is a biopharmaceutical
company developing innovative cell therapy
platforms for patients with cancer."
OUR MISSION:
"TO IMPROVE OUTCOMES FOR PATIENTS WITH CANCER"
Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen;
therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.
To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with
CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and
maximize tumor kill via combinatorial approaches otherwise not possible.
Coeptis Therapeutics Holdings, Inc. conducts its commercial operations primarily through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc.
Coeptis Therapeutics Holdings, Inc.
Corporate Headquarters
105 Bradford Road, Suite 420
Wexford, PA 15090
+1 (724) 934-6467
As of March 30, 2023 • 12:02 PM ET
As of March 30, 2023 • 12:02 PM ET
DATE/TIME | SOURCE | NEWS RELEASE |
---|---|---|
03/27/2023 10:47 AM EDT | SeekingAlpha | NBRV, JNCE and ALIM among healthcare movers |
03/27/2023 08:52 AM EDT | SeekingAlpha | IOVA, MQ and ONCS are among pre market gainers |
03/22/2023 08:30 AM EDT | InvestorBrandNetwork | InvestorNewsBreaks - Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal |
06/23/2022 05:27 PM EDT | SeekingAlpha | I-Mab Valuation Offers A Biotech Investment Opportunity |
04/22/2022 03:00 PM EDT | SeekingAlpha | Catalyst watch: Apple earnings, Twitter drama and media eyes on NAB Show |
04/19/2022 01:50 PM EDT | SeekingAlpha | Coeptis Therapeutics to merge with SPAC Bull Horn, uplist to Nasdaq |
04/13/2022 07:48 AM EDT | SeekingAlpha | Statera Biopharma stock soars 31% on potential drug platform acquisition by Coeptis Therapeutics |
05/18/2021 08:53 AM EDT | SeekingAlpha | Coeptis inks exclusive option agreements with VyGen-Bio |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for
information purposes only.
No stock exchange has approved or disapproved of the information here.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |